 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | tinodasertib (AUM001) / AUM Biosci
Journal: Design, synthesis and biological evaluation of MNK-PROTACs. (Pubmed Central) - Dec 20, 2024
In this study, DS33059, a small-molecule compound modified based on the ongoing clinical trials drug ETC-206, was chosen as the target protein ligand...The protein degradation assay showed that compound II-5 had good capability to degrade MNK1. The MNK-PROTACs strategy represents a new direction in treating tumors and deserves further exploration.
- tinodasertib (AUM001) / AUM Biosci
Safety, tolerability, and preliminary efficacy of tinodasertib as a monotherapy or in combination with pembrolizumab or irinotecan in metastatic colorectal cancer: Interim results from a phase II open-label, dose-finding, run-in and cohort expansion study. (Level 1, West Hall; Poster Bd #: G21) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_845;
P2
Clinical Trial Registration Number: NCT05462236. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- AUM001 / AUM Biosci
Immunomodulatory and anticancer effects of cyclical gemcitabine/nab-paclitaxel with continuous dosing of tinodasertib (AUM001) in preclinical KPC model (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_8157;
Additionally, the maintenance of AUM001 may enhance the decrease in pro-oncogenic protein expression and remodel the tumor immune microenvironment. In conclusion, continuous dosing of AUM001 following the cessation of chemotherapy could stabilize the tumor state, potentiating its application in clinical settings as maintenance therapy for PDAC.
- arsenic trioxide / Generic mfg.
Reclaiming a dirty drug: What is the context of vulnerability to arsenic trioxide in glioblastoma? (Section 29) - Mar 5, 2024 - Abstract #AACR2024AACR_6827;
These findings further implicate MNK1 activity and cellular response to oxidative stress as markers of ATO sensitivity, however they are not the sole determinates of response. Understanding of the mechanism of action for idiopathic compounds may allow for the discovery of molecular signatures of sensitivity, improving patient selection for clinical trials and the development of new combination approaches to combat resistance in other tumor types.
- || tinodasertib (AUM001) / AUM Biosci
Trial primary completion date, Metastases: KEYNOTE-D65: MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 2, 2024
P2, N=120, Recruiting, Sponsor: AUM Biosciences Pte Ltd
Understanding of the mechanism of action for idiopathic compounds may allow for the discovery of molecular signatures of sensitivity, improving patient selection for clinical trials and the development of new combination approaches to combat resistance in other tumor types. Trial primary completion date: Aug 2023 --> Sep 2024
- AUM001 / AUM Biosci
AUM001 potentiates the anti-tumor activity of gemcitabine in an AsPC-1 PDAC model (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_580;
Pharmacodynamic analysis suggests that AUM001 may potentiate the reduction in pro-tumorigenic protein expression and slow the tumor growth kinetics. This is the first study depicting clinical activity of AUM001 in combination with chemotherapy for the treatment of PDAC.
- AUM001 / AUM Biosci
Continuous dosing of AUM001 with cyclical gemcitabine/nab-paclitaxel to maintain the tumor growth kinetics in KPC xenograft model. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4810;
Pharmacodynamic analysis also suggests that AUM001 may potentiate the reduction in pro-tumorigenic protein expression. This is the first study depicting the continuous dosing of AUM001 after cessation of chemotherapy could help to maintain the tumor state, facilitating its possible use in clinics as maintenance therapy in PDAC.
- ||| tinodasertib (AUM001) / AUM Biosci
Enrollment open, Trial initiation date, Metastases: KEYNOTE-D65: MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 25, 2023
P2, N=120, Recruiting, Sponsor: AUM Biosciences Pte Ltd
This is the first study depicting the continuous dosing of AUM001 after cessation of chemotherapy could help to maintain the tumor state, facilitating its possible use in clinics as maintenance therapy in PDAC. Not yet recruiting --> Recruiting | Initiation date: Oct 2022 --> Apr 2023
- | tinodasertib (AUM001) / AUM Biosci
New P2 trial, Metastases: KEYNOTE-D65: MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 18, 2022
P2, N=120, Not yet recruiting, Sponsor: AUM Biosciences Pte Ltd
- | tinodasertib (AUM001) / AUM Biosci
Enrollment change, Trial withdrawal, Combination therapy, Metastases: Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies (clinicaltrials.gov) - Oct 25, 2018
P1b, N=0, Withdrawn, Sponsor: D3 (Drug Discovery and Development), A*STAR Research Entities
Not yet recruiting --> Recruiting | Initiation date: Oct 2022 --> Apr 2023 N=63 --> 0 | Recruiting --> Withdrawn
- ||| tinodasertib (AUM001) / AUM Biosci
New P1 trial, Combination therapy, Metastases: Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies (clinicaltrials.gov) - Jan 30, 2018
P1b, N=63, Not yet recruiting, Sponsor: D3 (Drug Discovery and Development), Biomedical Sciences Institute